Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Veracyte (NASDAQ: VCYT) has announced significant findings published in European Urology Oncology regarding its Decipher Prostate Genomic Classifier. The study indicates that Decipher scores are highly correlated with PSMA PET upstaging in high-risk prostate cancer patients, suggesting that these patients may benefit from intensified systemic treatment. The Decipher Prostate score, ranging from 0 to 1, helps identify metastatic disease risk, with ongoing Phase 3 clinical trials (NRG-GU009, NRG-GU010) evaluating its role as a predictive biomarker. The findings emphasize the importance of accurately identifying high-risk patients to tailor treatment accordingly, potentially improving patient outcomes.
Veracyte, Inc. (Nasdaq: VCYT) will announce its financial results for Q1 2023 on May 4, 2023, after market close. A conference call will take place at 4:30 p.m. Eastern Time on the same day, where management will discuss the results and give a business update. Investors can participate via a link provided in the PR. Veracyte focuses on transforming cancer care through high-performance diagnostics, aiding clinicians in making informed decisions for challenging diseases, including various cancers and interstitial lung diseases. The company aims to make its tests available both in the U.S. and globally, enhancing patients’ diagnostic timelines and treatment options.
Veracyte (Nasdaq: VCYT) announced that seven abstracts showcasing findings from the Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting from April 28 to May 1, 2023, in Chicago. The abstracts emphasize the clinical utility of the Decipher Prostate Genomic Classifier, aiding treatment decisions for prostate cancer patients. Notable presentations include studies on Molecular Correlates with PSMA Expression and the Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome. Veracyte aims to utilize this research to enhance patient care and treatment outcomes, reinforcing its commitment to evidence-based cancer treatment.